Study on Osimertinib and Cyclosporine A to Improve Treatment in Advanced Non-Small Cell Lung Cancer

Inclusion Criteria

• Must be 18 years or older and able to give informed consent.
• Have a confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations, verified by standard testing.
• Either have not started EGFR TKI therapy or may have started osimertinib within three weeks of meeting the study criteria, with no prior chemotherapy for metastatic disease.
• Have at least one measurable tumor that has not been treated with radiation.
• Have a performance status score of 0 to 2, indicating full activity or some restriction in strenuous activities.
• Have adequate organ function.
• Agree to use effective birth control if there is a potential for pregnancy.

Exclusion Criteria

• Women who are pregnant or breastfeeding.
• Have received radiation therapy within one week before starting the study treatment, unless already on osimertinib.
• Have had major surgery within two weeks before starting the study treatment, unless already on osimertinib.
• Have taken an investigational drug recently.
• Are taking medications or supplements that strongly affect liver enzymes (CYP3A4).
• Have severe or uncontrolled health conditions, such as high blood pressure or bleeding disorders.
• Have active infections like hepatitis B, hepatitis C, or HIV.
• Have digestive issues that prevent taking the study drugs.
• Have heart rhythm problems or a family history of sudden death.
• Have a history of lung diseases that required steroid treatment.
• Have allergies to the study drugs or similar medications.
• Have a history of autoimmune diseases, except for Hashimoto's thyroiditis.